Investor Presentaiton
COSMOS-Colon Update: Stage II/III
completely resected (RO) population
RFS Based on 4 Week Post-Surgery ctDNA
Detection
INVESTOR 20
DAY 23
Probability of
Recurrence-Free Survival
100
50
+/- ACT
ctDNA Not Detected (n=121)
HR 10.8 (95% CI, 1.98-60.5)
ctDNA Detected (n=14)
0
12
24
36
Time Since Surgery (mo)
No. at risk
ctDNA not detected 121
ctDNA detected
14
115
10
98
6
12
10
36M RFS
(95% CI)
80%
Sensitivity
prior to or at recurrence
99%
Specificity
(sample-level)
Data to be included in Medicare CRC
surveillance submission
No. of
ctDNA status
Events /
Total No.
Median
RFS
12M RFS
(95% CI)
24M RFS
(95% CI)
Not Detected
11/121
NR
Detected
9/14
18.0mo
95.0%
(89.3-97.7)
64.3%
(34.3-83.3)
90.7%
(83.9-94.8)
40.2%
30.1%
(15.1-64.4) (8.4-56.0)
90.7%
(83.9-94.8)
GUARDANT™ ACT = adjuvant chemotherapy, Clinical trial information: UMIN000037765
68View entire presentation